Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 224

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 224
---
, a global public company and leader in minimally invasive, procedurally
integrated spine solutions. Prior to NuVasive, he spent two years in the private equity space at Imaging Advantage and Cole Parmer
as executive vice president and chief financial officer. Imaging Advantage was acquired by Envision in 2015. In 2014, he served as the
executive vice president and chief financial officer for Questcor Pharmaceuticals which was acquired by Mallinckrodt in a $5.6B transaction.
Mr. Asarpota also spent a decade at Life Technologies, a global life sciences company where he was responsible for helping scale
the organization, driving growth through organic and M&A channels. During his tenure, the company revenue grew from approximately
$1B to more than $4B in 2014, leading to the company’s sale to Thermo Fisher for $13.6 billion that year. Prior to Life Technologies,
Mr. Asarpota spent 11 years at GE in several finance leadership roles. Mr. Asarpota holds a M.B.A. from Marquette University
and a Bachelor of Commerce from the University of Bombay. We believe that Mr. Asarpota is well-qualified to serve as a director of
our company based on his healthcare focused experience.

<div align='center'>131</div>

Lauren Chung — Lauren
Chung has served as a director since July 2025. Since November 2019, Dr. Chung has served as chief executive officer of
MINLEIGH LLC, identifying, evaluating and partnering with companies for investments and strategic, operational, and commercial opportunities,
and venture partner at Yozma Group. From May 2017 to November 2019, Dr. Chung was an Equity Research Managing Director
at WestPark Capital. From August 2016 to April 2017, Dr. Chung as in equity research at Maxim Group. Previously, Dr. Chung
founded and served as chief operating officer and chief compliance officer of Tokum Capital Management, a global healthcare investment
fund. Prior to that, she managed healthcare investment portfolios at institutional investment firms. Dr. Chung serves as director
of Todos Medical Ltd. Dr. Chung previously served as director of Cure Pharmaceutical Holding Corp from August 2019 until November 2021,
UltraSight, Inc from December 2020 to December 2021, and AdiTxt, Inc. from June 2021 until December 2021. Dr. Chung
holds a Ph.D. in